{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:10:18Z","timestamp":1790827818373,"version":"4.1.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Small cell lung cancer (SCLC) is marked by an exceptionally high proliferative rate and poor prognosis. Given its high propensity to metastasize, nearly two-thirds of SCLC patients are diagnosed with extensive-stage (ES) disease when surgery is not a treatment option anymore. Over several decades, only minimal changes have been made in the therapeutic armamentarium of ES-SCLC. Recently, however, several new therapeutic avenues were defined, thus renewing the hope for patients with this recalcitrant cancer. Here, we present an overview of the most current therapeutic advances in ES-SCLC focusing in particular on consolidative thoracic radiation therapy (cTRT) and chemo-immunotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The incorporation of immunotherapy in the standard-of-care of ES-SCLC patients and the resulting outcomes are both a remarkable hallmark of progress and a disappointment. Indeed, chemo-immunotherapy with or without cTRT and prophylactic cranial irradiation contributes to longer survival outcomes with minimal toxicity rates in well selected and properly monitored patients. Nevertheless, the gain in overall survival is still modest relative to that seen in many other solid tumors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Despite the encouraging results, further clinical trials are needed to determine the efficacy and safety of these therapeutic approaches, and moreover, to identify new predictive biomarkers of response.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000000911","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T08:00:06Z","timestamp":1669276806000},"page":"54-60","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Thoracic irradiation as consolidation therapy in patients with extensive-stage small cell lung cancer"],"prefix":"10.1097","volume":"35","author":[{"given":"Judit","family":"Berta","sequence":"first","affiliation":[{"name":"National Koranyi Institute of Pulmonology, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"R\u00f3zs\u00e1s","sequence":"additional","affiliation":[{"name":"National Koranyi Institute of Pulmonology, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Megyesfalvi","sequence":"additional","affiliation":[{"name":"National Koranyi Institute of Pulmonology, Budapest, Hungary"},{"name":"Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary"},{"name":"Department of Thoracic Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyula","family":"Ostoros","sequence":"additional","affiliation":[{"name":"National Koranyi Institute of Pulmonology, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"D\u00f6me","sequence":"additional","affiliation":[{"name":"National Koranyi Institute of Pulmonology, Budapest, Hungary"},{"name":"Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary"},{"name":"Department of Thoracic Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"},{"name":"Department of Translational Medicine, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.omto.2021.02.004","article-title":"Molecular profiles of small cell lung cancer subtypes: therapeutic implications","volume":"20","author":"Schwendenwein","year":"2021","journal-title":"Mol Ther Oncolytics"},{"issue":"(13\u201314)","key":"R3-20250526","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1101\/gad.314815.118","article-title":"POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer","volume":"32","author":"Huang","year":"2018","journal-title":"Genes Dev"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"100883","DOI":"10.1016\/j.adro.2021.100883","article-title":"Consolidative thoracic radiation therapy after first-line chemotherapy and immunotherapy in extensive-stage small cell lung cancer: a multi-institutional case series","volume":"7","author":"Diamond","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"210079","DOI":"10.1183\/16000617.0079-2021","article-title":"Recent developments in the treatment of small cell lung cancer","volume":"30","author":"Hiddinga","year":"2021","journal-title":"Eur Respir Rev"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","article-title":"SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization","volume":"15","author":"Baine","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/path.5922","article-title":"Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study","volume":"257","author":"Megyesfalvi","year":"2022","journal-title":"J Pathol"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/mco2.105","article-title":"Therapeutic advances in nonsmall cell lung cancer: focus on clinical development of targeted therapy and immunotherapy","volume":"2","author":"Cheng","year":"2021","journal-title":"MedComm"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"a038240","DOI":"10.1101\/cshperspect.a038240","article-title":"Advances in small-cell lung cancer (SCLC) translational tesearch","volume":"11","author":"Drapkin","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s40425-019-0690-1","article-title":"Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges","volume":"7","author":"Pavan","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study","volume":"38","author":"Rudin","year":"2020","journal-title":"J Clin Oncol"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"S1186","DOI":"10.1016\/j.jtho.2021.08.666","article-title":"P63.10 safety of simultaneously performed radiotherapy in patients with small-cell lung cancer undergoing atezolizumab treatment","volume":"16","author":"Galuba F","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R17-20250526","first-page":"9","article-title":"Role of consolidative thoracic radiotherapy for extensive-stage small cell lung cancer: trod thoracic oncology study group 08-006 multiinstitutional study","volume":"37","author":"Yavas","year":"2022","journal-title":"Turk J Oncol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"833478","DOI":"10.3389\/fonc.2022.833478","article-title":"Benefits of prophylactic cranial irradiation in the MRI era for patients with limited stage small cell lung cancer","volume":"12","author":"Qi","year":"2022","journal-title":"Front Oncol"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(17)30230-9","article-title":"Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","article-title":"Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial","volume":"385","author":"Slotman","year":"2015","journal-title":"Lancet"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1200\/JCO.20.03364","article-title":"Radiation therapy for small-cell lung cancer: ASCO guideline endorsement of an ASTRO guideline","volume":"39","author":"Daly","year":"2021","journal-title":"J Clin Oncol"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"215719","DOI":"10.1016\/j.canlet.2022.215719","article-title":"Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy","volume":"541","author":"Tian","year":"2022","journal-title":"Cancer Lett"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13014-021-01773-x","article-title":"Clinical outcomes of extensive-stage small cell lung cancer patients treated with thoracic radiotherapy at different times and fractionations","volume":"16","author":"Han","year":"2021","journal-title":"Radiat Oncol"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/onco.13752","article-title":"FDA approval summary: atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer","volume":"26","author":"Mathieu","year":"2021","journal-title":"Oncologist"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3389\/fonc.2020.01146","article-title":"Current management and progress in radiotherapy for small cell lung cancer","volume":"10","author":"Tjong","year":"2020","journal-title":"Front Oncol"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ijrobp.2020.09.031","article-title":"Prospective single-arm phase 1 and 2 study: ipilimumab and nivolumab with thoracic radiation therapy after platinum chemotherapy in extensive-stage small cell lung cancer","volume":"109","author":"Perez","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"19","author":"Ganti","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2020.12.045","article-title":"Radiotherapy, immunotherapy, and the tumour microenvironment: turning an immunosuppressive milieu into a therapeutic opportunity","volume":"502","author":"Donlon","year":"2021","journal-title":"Cancer Lett"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3390\/cells10040930","article-title":"Biomarkers of radiotherapy-induced immunogenic cell death","volume":"10","author":"Vaes","year":"2021","journal-title":"Cells"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.21037\/tlcr-20-305","article-title":"Thoracic radiotherapy in small cell lung cancer-a narrative review","volume":"10","author":"Levy","year":"2021","journal-title":"Transl Lung Cancer Res"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T23:02:36Z","timestamp":1748300556000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000911","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]}}}